We largely maintain our FY20E revenue (in US$). We cut our EBIT margin forecast to 25.2% vs. 26.4% and also cut our EPS forecast by 4.3%. We introduce FY21 financials and forecast revenue (US$)/EPS CAGR of 11%/9.9% over FY19-21E. We maintain ACCUMULATE with new TP of Rs2,228 (vs. Rs2,084 earlier) based on 22x FY21E. Key Highlights and Investment Rationale Q4FY19 see strong revenue growth of 2.4%/12.7% QoQ/YoY in CC Both QoQ CC growth and US$ growth of 2.8% was in-line with our forecast. Life Sciences & Healthcare (7.7% of revenue; +18.2% YoY in CC) and Regional markets &...